Eidelman Virant Capital’s Corcept Therapeutics CORT Stock Holding History

Eidelman Virant Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,000	Closed	-$140K	–	105
2018 Q3	$140K	Hold	10,000	–	–	0.07%	106
2018 Q2	$157K	Sell	10,000 -30,000	-75%	-$522K	0.1%	94
2018 Q1	$658K	Hold	40,000	–	–	0.43%	61
2017 Q4	$722K	Hold	40,000	–	–	0.42%	65
2017 Q3	$722K	Sell	40,000 -12,000	-23%	-$179K	0.43%	65
2017 Q2	$613K	Buy	+52,000	New	+$565K	0.35%	72

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eidelman Virant Capital's CORT Position: Q4 2018 in Review

Eidelman Virant Capital sold out of Corcept Therapeutics (CORT) in Q4 2018, closing a stake of 10,000 shares — an estimated $140K sold.

Eidelman Virant Capital first reported a position in CORT in Q2 2017 and held it in 6 quarters. The position peaked at $722K in Q4 2017. 222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

Eidelman Virant Capital reported no remaining Corcept Therapeutics position as of Q4 2018 after selling out during the quarter.
Eidelman Virant Capital sold 10,000 Corcept Therapeutics shares in Q4 2018, an estimated $140K.
Eidelman Virant Capital first reported a position in Corcept Therapeutics in Q2 2017 and held it in 6 quarters.
Eidelman Virant Capital's Corcept Therapeutics position peaked at $722K in Q4 2017.
222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on Eidelman Virant Capital's 13F filing for Q4 2018, filed 18 Jan 2019.